A two-phase study model for the standardization of HER2 immunohistochemical assay on invasive ductal carcinoma of the breast

Journal of the Medical Association of Thailand

Volumn 88, Issue 11, 2005, Pages 1680-1688

  Sampatanukul, Pichet ^a   Chaiwun, Benjaporn ^b   Wongwaisayawan, Sansanee ^c   Suwanagool, Parvinee ^d   Vinyuvat, Songkhun ^e   Karalak, Anant ^f   Praditphol, Niphon ^g   Paueksakon, Paisit ^h   Ruangvejvorachai, Preecha ^a   Field, Andrew S ⁱ   Wannakrairot, Pongsak ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Ministry of Public Health

^f NATIONAL CANCER INSTITUTE   (United States)

^g RAJAVITHI HOSPITAL   (Thailand)

^h PHRAMONGKUTKLAO HOSPITAL   (Thailand)

ⁱ ST VINCENT S HOSPITAL   (Australia)

Author keywords

Breast carcinoma; Guideline; HER2; IHC; Immunohistochemistry; Standardization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; COLORING AGENT;

ARTICLE; BREAST CARCINOMA; CLINICAL PROTOCOL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; SCORING SYSTEM; STAINING; BREAST TUMOR; FEMALE; IMMUNOLOGY; METHODOLOGY; PAGET NIPPLE DISEASE; PATHOLOGY; PROTO ONCOGENE; STANDARD; THAILAND; THEORETICAL MODEL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLINICAL PROTOCOLS; COLORING AGENTS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MODELS, THEORETICAL; PATHOLOGY, CLINICAL; RECEPTOR, ERBB-2; THAILAND;

EID: 33645242018     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Martin N, Cheirsilpa A. Breast. In: Sriplung H, Sontipong S, Martin N, Wiangnon S, Vootiprux V, Cheirsilpa A, et al, editors. Cancer in Thailand Vol. III, 1995-1997. Bangkok : Bangkok Medical Publisher 2003, 47-8.
2. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, et al. American Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clincal Oncology. J Clin Oncol 2001; 19: 1865-78.
3. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, et al. Current perspectives on HER2 testing: A review of national testing guidelines. Mod Pathol 2003; 16: 173-82.
4. Bilous M, Ades C, Armes J, Bishop J, Brown R, Cooke B, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 2003; 12: 92-8.
5. van de Vijver M. Emerging technologies for HER2 testing. Oncology 2002; 63(Suppl): 33-8.
6. Bilous M. HER2 testing recommendations in Australia. Pathology 2001;33:425-7.
7. Hanna W, O'Malley FO. Updated recommendations from the HER2/neu consensus meeting - Toronto, Ontario, 7 September, 2001. Curr Oncol 2002; 9: S18-20.
8. Penault-Llorca F, Balaton A, Sabourin JC, Le Doussal V. Immunohistochemical evaluation of HER2 status in infiltrating breast cancers: development of technical protocol and reading of results - recommendations. Ann Pathol 2002; 22: 150-7.
9. Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, et al. Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological Committee for Optimal use of Trastuzumab). Breast Cancer 2001; 8: 316-20.
10. Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: 890-2.
11. Field AS, Chamberlain NL, Tran D, Morey AL. Suggestions for HER-2/neu testing in breast carcinoma, based on a comparison of immunohistochemistry and fluorescence in situ hybridisation. Pathology 2001; 33: 278-82.
12. Penault-Llorca F, Adelaide J, Houvenaaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of erbB2 in human breast cancer: impact of fixation. J Pathol 1994; 173: 65-75.
13. F Hoffmann-La Roche Ltd. & Breast International Group (BIG). Study procedure and administrative manual. Protocol No. BIG 01-01/BO16348 2001, p10.
14. Press MF, Hung G, Godolphin W, Slamon J. Sensitivity of HER-2/neu antibodies in archive tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Research 1994; 54: 2771-7.
15. Tsuda H, Sasano H, Akiyama F, Kurosumi M, Hasegawa T, Osamura RY, et al. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int 2002; 52: 126-34.
16. Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H. Interobserver reproducibility of HER-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol 2002; 118: 693-8.
17. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing - national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002; 94: 852-4.
18. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.
19. Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 2001; 116: 806-10.
20. His ED, Tubbs RR. Editorial. Guidelines for HER2 testing in the UK. J Clin Pathol 2004; 57: 241-2.